Results 81 to 90 of about 80,577 (303)

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Janus kinase inhibitors in autoimmune diseases [PDF]

open access: yesAnnals of the Rheumatic Diseases, 2013
Biological therapies directed at proinflammatory cytokines have irrevocably changed the landscape of treatment of rheumatoid arthritis (RA) and other autoimmune diseases. With the advances in our knowledge in cytokine signalling, the question emerges whether targeting intracellular signalling might also be a safe and efficacious strategy. Janus kinases
John J, O'Shea   +4 more
openaire   +2 more sources

Interferon-γ Suppresses Intestinal Epithelial Aquaporin-1 Expression via Janus Kinase and STAT3 Activation - Table 3 [PDF]

open access: yes, 2015
Interferon-γ Suppresses Intestinal Epithelial Aquaporin-1 Expression via Janus Kinase and STAT3 Activation - Table 3
Michael A. Peplowski (707493)   +6 more
core   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley   +3 more
wiley   +1 more source

Assay Development and Inhibitor Screening for Janus Kinase 2 [PDF]

open access: yes, 2023
Janus kinase 2 (JAK2) is an essential mediator of hematopoietic and growth signaling in cells. It signals as a part of the Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway, which ultimately regulates gene expression by
Pölläniemi, Angelika
core  

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

open access: yesBiotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady   +6 more
wiley   +1 more source

Therapeutic effects of janus kinase inhibitors [PDF]

open access: yes
Janus kinase (JAK) inhibitors are small synthetic molecules which can easily enter the intracellular space and inhibit janus kinases, which renders the janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway to be nonfunctional.
Ntwali, Arnaud
core  

Biomaterials for modulating cellular responses of endogenous tendon stem/progenitor cells: A promising avenue for tendon regeneration

open access: yesBMEMat, EarlyView.
This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu   +9 more
wiley   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

open access: yesCancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang   +4 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Home - About - Disclaimer - Privacy